Shaji Kumar, ASCO20: Efficacy and Toxicity in the Randomised Phase III ENDURANCE Trial in Myeloma

Shaji Kumar: Comparing KRd With VRd in Newly Diagnosed MyelomaПодробнее

Dr. Kumar on Treatment Discontinuation in the ENDURANCE Myeloma TrialПодробнее

Shaji Kumar, MD, shares results of the Phase 3 study regarding 1st line multiple myeloma treatmentПодробнее

Shaji Kumar, MD, shares the design and outcomes of the CARTITUDE-1 trial regarding multiple myelomaПодробнее

Dr. Kumar: Results of the ENDURANCE Trial Support Standard of Care Treatment for MyelomaПодробнее

Dr. Kumar on Takeaways From the ENDURANCE Trial in Multiple MyelomaПодробнее

Additional Advances in Multiple Myeloma Research and Clinical Trials With Shaji Kumar, MDПодробнее

Jorge E Cortes, ASCO20: 5-Year Analysis of the Phase II PACE Trial of Ponatinib in Ph+ leukemiaПодробнее

Shaji Kumar, ASCO 2018 – Advances in treatment approaches and guidelines for multiple myelomaПодробнее

Efficacy and Toxicity of Selinexor: Importance of Dose Intensity and Post Progression OutcomesПодробнее

Should Frontline Myeloma Treatment Include a 3- or 4-Drug Regimen?Подробнее

Shaji Kumar, MD, discusses the most exciting treatment options for multiple myeloma todayПодробнее

Dr. Kumar on the Safety and Efficacy of Venetoclax in MyelomaПодробнее

MCP 60 Seconds With Dr Shaji Kumar on Muiltple MyelomaПодробнее

Debate: Is allotransplant relevant today in myeloma? - NoПодробнее

CD38: a promising target for multiple myeloma antibody therapyПодробнее

An overview of the toxicities associated with immunotherapy in multiple myelomaПодробнее

Updated Efficacy and Safety Results of the Phase 3 CANDOR studyПодробнее